TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
TNFR1 -383 A˃C polymorphism and ankylosing spondylitis in a Russian Caucasian population: a preliminary study.
|
28363009 |
2017 |
TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci.
|
26974007 |
2016 |
TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism (rs1800693) of TNFRSF1A (type 1 tumour necrosis factor receptor) encodes a potentially anti-inflammatory soluble truncated form of the p55 receptor, which is associated with predisposition to multiple sclerosis but protection against ankylosing spondylitis (AS).
|
29535371 |
2019 |
TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P < 5 × 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P < 5 × 10(-6) overall, with support in each of the three datasets studied).
|
21743469 |
2011 |
TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci.
|
23749187 |
2013 |
TNFRSF1A
|
0.200 |
Biomarker
|
disease |
BEFREE |
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept.
|
15818694 |
2005 |
TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Only rs1061622 was significantly associated with long-term efficacy of etanercept: the TG genotype of rs1061622 worsened ASAS20 and ASAS40 responses at 12 months (P = .021 and .041, respectively).The results suggest that TNFRSF1A and TNFRSF1B polymorphisms were associated with susceptibility, severity, and the long-term therapeutic efficacy of etanercept of patients with AS.
|
30075559 |
2018 |
TNFRSF1A
|
0.200 |
Biomarker
|
disease |
BEFREE |
Single nucleotide polymorphism (SNP) and haplotype analyses were conducted based on determined NLRP3 and TNFRSF1A among AS patients.
|
28116820 |
2017 |
TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
SNPs in TNFRSF1A (rs4149577, p = 8.2 × 10⁻⁴), STAT3 (rs2293152, p = 0.0015; rs1053005, p = 0.017) and ERAP1 (rs27038, p = 0.0091; rs27037, p = 0.0092) were significantly associated with AS in Han Chinese.
|
21068102 |
2011 |
TNFRSF1A
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Soluble TNFRI levels correlate with ESR and CRP in AS.
|
20595269 |
2010 |
TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The aim of the present study was to examine the role of the polymorphisms 36A>G (TNFR1), 676T>G (TNFR2), -857C>T (TNF-alpha), -308G>A (TNF-alpha), and -238G>A (TNF-alpha) in AS susceptibility.
|
19772798 |
2009 |
TNFRSF1A
|
0.200 |
Biomarker
|
disease |
BEFREE |
These studies confirm the weak genetic associations between AS and TNFRSF1A.
|
22272576 |
2012 |
TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
This preliminary study is the first assessing the association of the -383 A/C TNFR1 polymorphism with AS, although it has the limitation of a small sample size.
|
21789618 |
2012 |
TNFRSF1A
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We replicated associations between AS and the polymorphisms in TNF (rs1800629), TNFRSF1A (rs4149570), and IL23R (rs11209026).
|
30208882 |
2018 |